Scientific breakthroughs in blood cancer are advancing faster than ever. For community-based oncologists, staying current with the latest research and treatment innovations, especially those coming from top academic centers, can be a real challenge.

That’s why we created Treating Blood Cancer in the Community, a cost-free, independent video resource designed to deliver concise, expert insights directly to you and your clinical team.

Through short, high-impact clips, leading clinician-researchers from institutions such as Memorial Sloan Kettering, Mount Sinai, and others share how they are evolving care based on the most recent clinical trial data and drug approvals. Just as importantly, they offer guidance on how academic and community oncology teams can work together to improve patient outcomes.

Now Available: MDS

Dr. Tremblay reflects on:

• The role of molecular testing in MDS managemenT
• ESA strategies and when to use Luspatercept
• Practical infection control
• Other updates in MDS care

“I would prioritize sending molecular testing for evaluation in those patients where there might be some therapeutic options available based on this mutational profile.”
​Douglas Tremblay, MD, Ichan School of Medicine at Mount Sinai

Myelofibrosis

Dr. Mascarenhas reflects on:

• why early referral to a specialist matters more than ever
• when to speak with a patient about transplant
• managing infection risk and toxicities
• treating for disease modification and extended survival

“We (now) have a lot of different active agents… In this field, we’re looking for deeper responses to modify the disease course and extend survival. So, refer early.”
John Mascarenhas, Ichan School of Medicine at Mount Sinai

Acute Lymphoblastic Leukemia (ALL)

ALL expert Mark B. Geyer, MD, at Memorial Sloan Kettering shares insight on:

• How and when to collaborate with a specialized care center
• Management of toxicities, and the best way to monitor and manage them

“Community oncologists can participate in the care of children or adults with acute lymphocytic leukemia (ALL) during a number of different phases of treatment. . .  Blinatumomab is now approved in nearly every phase of treatment for patients with B-cell ALL.”

Acute Myeloid Leukemia

AML specialist Eytan Stein, MD, Chief, Leukemia Service at Memorial Sloan Kettering, shares key insights on:

• Elderly patients with AML
• Key infection prophylaxis strategies in AML
• Essential supportive measures during AML therapy
• Transplant decisions in AML patients
• New targeted therapy for KMT2A-rearranged relapsed/refractory AML

“At our center, it is not uncommon now that we’re transplanting patients up to the age of 75. It’s not the age that determines transplant, it’s the patient profile and comorbidities.”

Multiple Myeloma

In this video, multiple myeloma specialist Urvi Shah, MD, of Memorial Sloan Kettering shares key insights on:

• Combination drug therapies
• Steroid dose reduction
• Immune therapies and infection management
• CAR-T cell therapy
• Current clinical trial options

“It is better to do two, three or four drugs at lower doses than to do one drug at the full dose in terms of myeloma control and patient tolerability.”
- Urvi Shah, MD, Memorial Sloan Kettering

Diffuse Large B-Cell Lymphoma

Lymphoma expert Dr. Joshua Brody shares key insights on:

• The emerging role of bispecific antibodies in first- and second-line DLBCL treatment
• How he collaborates with community oncologists to manage treatment-related side effects

“Bispecific antibodies are absolutely transformational. We are already using them every day in third line and sometimes in second line DLBCL, by themselves and in combination with chemotherapies. These will unquestionably become part of second line therapy, and in my opinion, for DLBCL, in the very near future as part of frontline therapy.”  - Joshua Brody, MD, Director, Lymphoma Immunotherapy Program, Tisch Cancer Institute at Mount Sinai

Chronic Lymphocytic Leukemia

In this video, CLL clinician and researcher Adam Kittai, MD, Icahn School of Medicine at Mount Sinai, shares key insights on:

• The evolving role of watch-and-wait strategies in CLL management
• Choosing between fixed-duration and continuous therapy
• Drug class switching and sequencing

“When we think about patients with CLL who are currently on watch and wait, I like to think of them as being on active surveillance. We’re not just watching and waiting, we’re monitoring their symptoms, intervening when we can.” - Adam Kittai, MD, Icahn School of Medicine at Mount Sinai

Recent studies show that treatment approaches can vary between academic and community settings. These brief, expert-led segments are designed to support your practice by offering timely insights from academic leaders, delivered in a format that fits your busy schedule.

Support Your Patients With Free Educational Materials

Order patient-friendly booklets and resources to help your patients better understand their blood cancer diagnosis and treatment options.

The Story Behind HealthTree Foundation

Founded by myeloma patient and advocate Jenny Ahlstrom, HealthTree exists to close gaps in education, support, and research for blood cancer patients. What began as one patient's journey has grown into a comprehensive platform that empowers patients with knowledge and connection, while accelerating scientific discovery. Learn more about our story and mission.